Artiva Biotherapeutics, Inc. (ARTV) News
Track canonical SquawkNews coverage tagged to ARTV, Artiva Biotherapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-upSAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva
NEWS | Sep 23, 2026, 11:33 AM UTC
L
ARTV - Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
ARTV - Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
NEWS | Sep 23, 2026, 11:30 AM UTC
L
ARTV - Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
ARTV - Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
NEWS | Sep 17, 2026, 12:00 PM UTC
L
ARTV: Allogeneic NK cell therapy for refractory RA shows strong efficacy and advances to phase III
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing deep B-cell depletion and strong efficacy in early trials. Phase III is underway with robust funding, rapid community-based enrollm
NEWS | Sep 14, 2026, 07:38 PM UTC
L
ARTV: Allogeneic NK cell therapy for refractory RA shows strong efficacy, safety, and broad potential
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing strong efficacy and safety, with a pivotal phase III trial underway and broad expansion potential. Key milestones include updated c
NEWS | Sep 14, 2026, 07:15 PM UTC
L
ARTV advances pivotal Phase III trial in refractory RA
A novel NK cell platform is advancing in autoimmune disease with a pivotal Phase III trial in refractory RA targeting deep B-cell depletion, citing promising early efficacy and safety.
EQUITY | Sep 09, 2026, 04:05 PM UTC
M
ARTV advances pivotal Phase III trial for refractory RA
ARTV’s AlloNK cell platform is advancing in a pivotal Phase III trial for refractory RA. Enrollment is robust, with data updates expected by year-end and top-line results targeted for 2028.
EQUITY | Sep 09, 2026, 03:29 PM UTC
L
Artiva Biotherapeutics updates planned Allonk data and 2026 milestones
Artiva Biotherapeutics Inc provided an update on planned Allonk data disclosures and development milestones for the remainder of 2026.
EQUITY | Sep 08, 2026, 11:47 AM UTC
L
ARTV - Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 - Cli
ARTV - Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
EQUITY | Sep 08, 2026, 11:30 AM UTC
L
Artiva Biotherapeutics CEO Aslan Fred sells $690K in shares
Aslan Fred, a director and Chief Executive Officer, sold 61,888 shares in an automatic sell-to-cover under a reported Form 4 filing. Weighted average sale price was $11.1555 per share, totaling $690,391.
EQUITY | Sep 04, 2026, 08:12 PM UTC
L
Artiva Biotherapeutics to participate in September investor conferences
Artiva Biotherapeutics announced management will participate in upcoming investor conferences in September.
EQUITY | Sep 02, 2026, 12:37 PM UTC
L
ARTV - Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
ARTV - Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
EQUITY | Sep 02, 2026, 12:30 PM UTC
M
Insiders Buy HDSN, XAIR, ARTV, IONS Shares
Insiders purchase shares of four companies
EQUITY | Aug 03, 2026, 09:28 AM UTC